Secondary Marketplace / Trade Private Companies / Buy and Sell AZTherapies Stock
AZTherapies AZTherapies Stock
$401.38MM
Series C-1 Valuation, Aug 2020
Register To Buy and Sell Private Company Shares
For more details on financing and valuation of private companies, register or login today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Sign in

AZTherapies Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

AZTherapies Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
08/28/2020 Series C-1 $35MM $xx.xx $401.38MM Axiom Associates, Defta Partners, Drads Capital, Duopharma Biotech Berhad, Id Fund, Nextrans-Kclavis, Spinnaker Capital, Wexford Capital
Price per Share
$xx.xx
Shares Outstanding
5,185,185
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Axiom Associates, Defta Partners, Drads Capital, Duopharma Biotech Berhad, Id Fund, Nextrans-Kclavis, Spinnaker Capital, Wexford Capital
10/07/2019 Series C $37.5MM $xx.xx $285.08MM Cosine, Drads Capital, Ibs Capital, Spinnaker Capital, Wexford Capital
Price per Share
$xx.xx
Shares Outstanding
7,142,857
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.5x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Cosine, Drads Capital, Ibs Capital, Spinnaker Capital, Wexford Capital
06/18/2018 Series B $18.98MM $xx.xx $225.39MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
3,996,573
Liquidation Pref Order
1
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
11/20/2015 Series A-2 $6.11MM $xx.xx $157.32MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
1,569,540
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
11/20/2015 Series A $16.85MM $xx.xx $157.32MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
4,212,559
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
12/22/2014 Series A-1 $6.93MM $xx.xx $69.29MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
2,084,052
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
Company Details
AZTherapies is a biopharmaceutical company developing novel small molecules and biologic therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population.
Founded
2011
Post-Money Valuation 3
$401.38MM
Total Funding
$121.38MM
LFR Price per Share
$xx.xx
Last Funding Share Class
Series C-1
AZTherapies Stock FAQs
To buy and sell AZTherapies stock
Can you buy AZTherapies stock?
You can no longer buy AZTherapies stock on a secondary marketplace as this company ceased its operations. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
How to buy AZTherapies stock?
You can no longer buy AZTherapies stock on a secondary marketplace as this company ceased its operations. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
Can you sell AZTherapies stock?
You can no longer sell stock of AZTherapies on Forge as this company ceased its operations. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
How to sell AZTherapies stock?
You can no longer sell stock of AZTherapies on Forge as this company ceased its operations. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
To learn more about AZTherapies stock
Is AZTherapies a public company?
AZTherapies ceased its operations.
What is AZTherapies’ stock price?
AZTherapies ceased its operations so there is no stock price available.
What is AZTherapies’ stock ticker symbol?
AZTherapies ceased its operations so there is no stock ticker symbol.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.
Other Companies Like AZTherapies in the BioTech & Pharma Sector
Sector: Healthcare
Subsector: BioTech & Pharma
Last Funding Round
Company Forge Price Forge Price Change 5 Last Closed Trade Share Class Post-Money Valuation Price per Share Amount Raised
Affinia TherapeuticsAffinia Therapeutics----$xx.xxSeries B$365.7MM$xx.xx$110MM
Altos LabsAltos Labs----$xx.xxSeries C$6.33B$xx.xx$1.5B
ArsenalBioArsenalBio----$xx.xxSeries C$1.66B$xx.xx$327.5MM
Colossal BiosciencesColossal Biosciences----$xx.xxSeries B$1.01B$xx.xx$150MM
Isomorphic LabsIsomorphic Labs----$xx.xx--------
LoyalLoyal----$xx.xxSeries B-5$428.44MM$xx.xx$17.49MM
OwkinOwkin----$xx.xxSeries B-1$1.46B$xx.xx$50MM
Precision NeurosciencePrecision Neuroscience----$xx.xxSeries C$542.69MM$xx.xx$102MM
Xaira TherapeuticsXaira Therapeutics----$xx.xxSeries A$2.65B$xx.xx$500MM
Zenas BioPharmaZenas BioPharma----$xx.xx--------

Updated on: Jan 15, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.